225Ac-LaVO4 nanoparticles

225Ac-LaVO4 nanoparticles are radiolabeled lanthanum orthovanadate (LaVO4) nanoparticles doped with the alpha-emitting radioisotope actinium-225 (225Ac), developed by Oak Ridge National Laboratory for targeted radionuclide therapy (TRT). These nanoparticles are designed to encapsulate 225Ac and retain its decay daughters (such as francium-221 and bismuth-213) to mitigate off-target toxicity caused by daughter relocation. The surface of the nanoparticles is functionalized and conjugated with cancer-targeting ligands, such as those targeting HER2, to deliver cytotoxic alpha-particle radiation directly to cancer cells. Upon internalization via the endolysosomal pathway, the nanoparticles localize near the nucleus, where the high-energy alpha emissions induce double-strand DNA breaks, leading to effective cell death in HER2-positive breast cancer and other malignancies.

Other names

225Ac-LaVO4225Ac-doped lanthanum orthovanadate nanoparticles225Ac-radiolabeled lanthanum orthovanadate (LaVO4) nanoparticles225Ac-radiolabeled lanthanum orthovanadate nanoparticles